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The European Academy of Cancer Sciences (EACS) is an independent advi-
sory body of well-recognised medical specialists and researchers striving to
create a compelling interactive continuum of cancer research, from innova-
tive basic research to implementation of state-of-the-art evidence-based can-
cer care and prevention. Achieving the above will entail bridging high-quality
basic and preclinical cancer research to research on prevention, early detec-
tion and therapeutics as well as improving coordination of translational
research efforts across Europe. The latter is expected to be expedited through
quality assuring translational cancer research in Comprehensive Cancer Cen-
tres – entities that link research with the healthcare system – and networks of
cancer research centres. Achieving a critical mass of expertise, resources and
patients is crucial. Improving late translational research, which involves clini-
cal studies to assess effectiveness, and added value for the health care is also
a high priority. Both high-quality Big Data collections and the intelligent use
of these data will promote innovation in cancer research and support out-
comes research to assess clinical utility, quality of cancer care and long-term
follow-up of treated patients. The EACS supports the mission-oriented
approach recently proposed by the European Commission in Horizon Eur-
ope to deal with major challenges and would like to persuade the EU and its
member states to formally launch a mission in cancer to boost and streamline
the cancer research continuum in Europe. Building a coherent translational
cancer research continuum with a focus on patients and individuals at risk
will require, however, foresight as well as the extensive and continuous provi-
sion of evidence-based advice to inform policy.
1. The burden of cancer
Cancer is a major challenge for society, the healthcare
systems and the growing number of affected patients.
In the 40 European countries, cancer incidence in 2015
was 3.6 million with an expected increase to 4.3 mil-
lion in 2035. The rise in the ageing population is a pri-
mary reason for the incidence trends, although cancer
is also a significant cause of death before the age of
70. During the same 20-year period, the annual
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number of patients dying from cancer in the European
countries is predicted to increase from 1.8 to 2.3 mil-
lion (Ferlay et al., 2013). In addition, the steady
growth in the number of cancer survivors and the
more chronic nature of the disease – with its own
specific comorbidities and requirements for regular
monitoring – will further increase the burden on the
healthcare systems. In the European Union (EU), the
cost of cancer was estimated at 126 billion euros in
2009 (Luengo-Fernandez et al., 2013) with significant
differences per capita between countries.
The continuously growing insights in cancer biology
over the last decades have revealed an enormous com-
plexity and heterogeneity of human malignancies. This
complexity impacts the whole continuum of cancer
research, which includes fundamental research, transla-
tional, prevention and clinical research, outcomes
research, and cancer care. The combination of a rising
incidence and prevalence, the increasingly chronic nat-
ure of the disease, combined with the complexity and
associated costs of treatment – partly the result of the
often-exorbitant pricing of anticancer drugs – can
easily lead to a collapse of the healthcare systems. As
a result, substantial innovation in both prevention and
treatment is urgently needed.
To deal with these challenges, Europe must take coor-
dinated actions. Stakeholders to be involved include the
EU commission, national governments, health organi-
sations, professional societies, cancer centres, hospitals
and research institutes. This position paper provides the
viewpoints of the European Academy of Cancer Science
(EACS; www.europeancanceracademy.eu) regarding
the cancer research continuum and highlights specific
areas where initiatives should be taken. The primary
aim of the EACS is to increase awareness of these issues
and to help developing action plans. By proposing effec-
tive incentives for collaboration between stakeholders in
the different EU countries (and beyond) and by provid-
ing quality standards and assessment protocols for can-
cer centres and institutes, the EACS hopes – in
collaboration with other organisations with overlapping
aims – to contribute to an EU-wide more effective treat-
ment and prevention of cancer patients.
2. Present state of affairs
2.1. Addressing the fragmentation of cancer
research
An extensive analysis of European cancer research was
carried out in 2005–07 by the EU-project ‘Euro-
can+Plus’ initiated by former Commissioner Philippe
Busquin and supported by the European Parliament.
He considered that cancer research in Europe was frag-
mented and that many patients had no access to the
diagnostic services and therapeutic treatments that they
rightly demanded (http://www.europa.eu/rapid/press-re
lease_SPEECH-02-408_en.htm): ‘There was a clear
need to create a common European strategy for cancer
research’. The cancer community was asked to improve
coordination of cancer research activities in Europe
through already existing funding mechanisms. One
main recommendation of the project was the creation
of a platform for translational cancer research, com-
posed of interlinked centres with shared infrastructures
and collaborative projects to facilitate rapid advances in
knowledge and their translation into better cancer care
and prevention. The ‘Eurocan+Plus’ highlighted the
need for structuring translational cancer research,
which by definition focusses on issues directly relevant
for cancer patients. The aim was to identify strategies to
promote innovation across the whole cancer research
continuum (basic, prevention, preclinical, clinical and
outcomes research).
The project also stressed the increased need for com-
plex infrastructures to integrate the multiple compo-
nents of the research continuum. The Comprehensive
Cancer Centre (CCC), a structure that provides multi-
disciplinary academic expertise covering a substantial
stretch linking research and health care, was deemed
to be of critical importance. Due to a large number of
cancer patient subgroups and increased demands
regarding technological resources and competencies, a
close collaboration between CCCs was considered
essential; such partnership would provide the full spec-
trum of expertise and resources, as well as access to a
sufficient number of patients, both prerequisites for
innovative research and personalised/precision cancer
medicine.
The concerns articulated in the ‘Eurocan+Plus’ pro-
ject were taken seriously by the cancer community,
which organised itself to provide evidence-based advice
to inform policy. The aim was to persuade the Eur-
opean Commission (EC) to support FP7 (Framework
Programme 7) activities intended to structure transla-
tional cancer research and to improve cross-border
institutional collaborations. These efforts resulted in
the funding of the EurocanPlatform project, which
from 2011 to 2016 explored various strategies to
organise translational research by bridging basic/pre-
clinical research with clinical studies. One of the out-
comes was the establishment of Cancer Core Europe,
now a legal consortium consisting of seven large can-
cer centres (mainly CCCs) across Europe (Eggermont
et al., 2014). Besides providing a model of how better
coordination and critical mass might be organised, the
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bottom-up initiative created an ecosystem where the
three priorities of Commissioner Carlos Moedas, Open
Science, Open Innovation and Open to the World
could be interlinked, and where the social dimension
of science becomes evident. However, this initiative
also illustrated the many obstacles that can preclude
effective cross-border collaboration. In parallel, a con-
sortium of nine cancer prevention centres was estab-
lished (Cancer Prevention Europe) to support the
complete cancer prevention research continuum. A
Consortium Agreement was signed in February 2017,
with present plans to incorporate two more centres.
Other deliverables of the project included the estab-
lishment of a designation methodology for CCCs of
Excellence (for specific assessment of bench to bedside
research), developed in collaboration with the EACS
(Ringborg et al., 2018). Moreover, because educational
activities with a focus on translational cancer research
were limited, an annual international Summer School
in Translational Cancer Research was established in
2012, with the intention of fostering collaboration
between basic, translational and clinical researchers.
The school is now sustainable under the umbrella of
Cancer Core Europe.
The above developments emphasised the need for
EU-wide science policy as prerequisite for coordinating
cutting-edge cancer research, establishing adequate
funding mechanisms, harmonising the regulatory envi-
ronment and for eliminating disparities in cancer con-
trol among EU populations. Towards this end, the
EACS was established in 2009 with support from
ECCO (the European CanCer Organization). The
EACS is now a legal structure whose primary goal is
to boost innovation and research coordination, as well
as to establish state-of-the-art research infrastructures
with outreach to local hospitals and healthcare organi-
sations in order to achieve efficient and cost-effective
cancer prevention, treatment and care services
throughout Europe.
2.2. Cancer prevention research
It is impossible to optimise cancer control by improv-
ing treatment only, and as a result, an integrated
approach built on prevention, early detection and
treatment is critical. An estimated 40% reduction of
the cancer incidence can be achieved by fully imple-
menting present knowledge of prevention strategies.
Primary prevention aims at averting the exposure to
carcinogens and other cancer-promoting conditions,
several of which are common to the main noncommu-
nicable diseases. Here, proper legislation to encourage
behavioural changes, vaccination technologies and
medical prevention is a critical component. In particu-
lar, legislation focusing on reducing exposure to car-
cinogens, tobacco smoking being the most prominent
example, is a key policy issue rather than a scientific
one. Preventive cancer screening or secondary preven-
tion, aimed at removing precursor lesions known with
likelihood to progress to invasive cancer such as cervi-
cal cancer, colonic adenoma and melanoma, has
shown to be effective. However, for other cancers,
such as breast and prostate, the early lesions prone to
progress to invasive cancers are more difficult to diag-
nose. Identifying premalignant lesions that are likely
to progress is a strategic component of the research
aimed at understanding the drivers of tumour initia-
tion and tumour progression. For some common
malignant diseases, screening technologies for early
detection are in place, and population-based screening
programmes have been established in several European
countries for cervical, breast and colorectal cancer.
Critical research areas include the development of
improved diagnostic technologies, as well as method-
ologies for follow-up screening and outcome predic-
tion. Algorithms that can predict outcome in
individual patients combined with sophisticated devices
to monitor clinically relevant parameters over time can
revolutionise this field. Big Data approaches will likely
play an important role in their development. A com-
prehensive manuscript describing the Cancer Preven-
tion Europe strategy has recently been accepted for
publication (Forman et al., 2018).
The level of financial support for research in preven-
tion is roughly 7% of the cancer research budget.
Optimal allocation of resources for the different
research categories is a vital science policy question
(Cancer Research Partnership).
2.3. Therapeutic research
Surgery and radiotherapy, increasingly combined with
systemic treatment, can cure most patients with loca-
lised diseases. The great challenge is to make localised
treatment less mutilating. Incremental advances are
still made to make the treatment less harmful and to
control advanced loco-regional disease, but the great
challenge is to control disseminated cancer using some
form of systemic therapy. Therapeutic research focused
on primary as well as disseminated cancer is receiving
substantial emphasis thanks to the massive introduc-
tion of ‘omics’ techniques for the analysis of tumour
samples and liquid biopsies. Fostered by cancer biol-
ogy research, important progress has been made;
sophisticated combination therapies and immunothera-
pies have been developed that appear to be effective in
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several cancer subtypes. However, the majority of dis-
seminated cancers are resistant or develop resistance to
systemic treatment.
Significant investments to understand the complexity
of these tumours, their heterogeneity, their plasticity,
their genetic and epigenetic drift, the role of the
microenvironment and the failure of the immune system
to recognise and eradicate these tumours require signifi-
cant research efforts; basic cancer research has to pro-
vide the answers. Subsequently, the concepts coming
from these more fundamental studies must be validated
in relevant preclinical models before they are tested in
clinical trials. For this latter translational part, well-
organised CCCs focused on designing innovative data-
rich and deep clinical trials and capable of swiftly
recruiting a sufficient number of patients with a specific
biomarker signature are critical. Here, EU-wide collabo-
ration of cancer research centres as exemplified by Can-
cer Core Europe is of pivotal importance.
The EACS believes that Cancer Core Europe pro-
vides a model for establishing similar consortia with
sufficient critical mass (but not too large to keep the
consortia manageable and flexible) to recruit sufficient
numbers of patients. The advances made in trial
designs, allowing patients to be treated according to a
protocol based on molecular markers and response
profiles are expected to create timely new insights that
may lead to changes in clinical practice. These future
trials will, however, also require advanced method-
ologic skills and challenging trade-offs between statisti-
cal power and generalisability of findings from cancers
with molecularly defined malignancies (Hunter, 2016).
2.4. Bridging research and health care
As pointed out above, insights gained in research can
have a significant impact on the quality of cancer care;
patients are not willing to wait for new diagnostic and
treatment methodologies. To support innovation in
cancer care, the CCC is a critical structure, since by
definition a CCC integrates multidisciplinary cancer
care with research and education. Prevention can be
an integrated part of a CCC or a component of other
infrastructures.
Although CCCs appear best equipped to catalyse
this process, most clinical care is provided by clinics
outside the CCCs. Consequently, CCCs must be
charged with the responsibility to reach out and inter-
act closely with these clinical centres concerning the
quality of care, innovation and research collaboration.
Europe has two accreditation bodies for CCCs, the
OECI (Organization of European Cancer Institutes)
and the German Cancer Aid. Moreover, the EACS
offers a programme for Designation of CCCs of Excel-
lence assessing the quality of translational cancer
research. Therefore, it is important that accreditation
of CCCs also assesses the geographical outreach as an
independent parameter. Up-to-date clinical guidelines,
based on clinical practice guidelines provided by pro-
fessional organisations such as NCCN (National Com-
prehensive Cancer Network), ASCO (American
Society of Clinical Oncology), ESMO (European Soci-
ety for Medical Oncology), ESTRO (European Society
for Radiotherapy and Oncology), ESSO (European
Society of Surgical Oncology) and NICE (National
Institute for Health and Care Excellence) covering the
complete clinical pathway and linked to clinical cancer
registries, are needed to guide the implementation and
outcome of innovations within the healthcare systems.
The capability to couple registries from different coun-
tries will be of critical importance to collect statisti-
cally significant data, given the increasing stratification
of patients. By using real-world data, the clinical util-
ity of innovations can be evaluated, an important
aspect being the long-term follow-up of cancer
patients, which is presently an unmet need.
Cancer survivors represent an increasingly large pop-
ulation, and their well-being depends on the outcome of
therapeutic interventions, cancer care, post-treatment
monitoring, rehabilitation, tertiary prevention and, for
some, palliative care. Currently, there is an impressive
development of diagnostic technologies supporting both
prevention and therapeutic disciplines. Supportive care,
psychosocial oncology, rehabilitation and palliative care
are increasingly important for a growing patient popula-
tion living with cancer as a chronic disease. There is a
need to structure research on health-related quality-of-
life issues, and hence, it is important that the accredita-
tion methodologies in the long term will be able to
assess all areas of cancer care and prevention.
Innovative academic cancer research has identified
many new appealing drug targets. However, this has
resulted in increased marketing of anticancer drugs and
medical devices with insufficient information on effec-
tiveness. An explosion of the cost of treatments due to
the very high prices charged for drugs by many pharma-
ceutical companies is a threat to citizens’ access to state-
of-the-art therapies. This is an increasing concern
because costs might deprive patients of effective treat-
ment purely for economic reasons. This is not accept-
able and requires recalibration of how inventions made
by life sciences in academia – paid by society – can bene-
fit patients maximally at an affordable cost.
At present, Cancer Core Europe and Cancer Preven-
tion Europe are in the process of integrating therapeu-
tics and prevention strategies to identify and remedy, in
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partnership, existing gaps in the cancer care continuum.
By offering innovative approaches for cancer research,
links to the healthcare systems, development of quality-
assured multidisciplinary cancer care and the assessment
of long-term outcomes, such distributed infrastructures
are expected to serve as hubs to connect with other cen-
tres in Europe as well as in other continents.
Parallel to these developments, the EC recently
decided to tackle global challenges by moving from a
challenge-driven to a mission-oriented approach in
Horizon Europe; missions open new possibilities to
address significant societal challenges such as cancer,
as for the first time there is an open discussion and
analysis of the relationship between research and its
social impact (http://europa.eu/rapid/press-release_IP-
18-4041_en.htm). This development prompted Julio E.
Celis and Dainius Pavalkis – members of the RISE
High-level Group advising Commissioner Carlos Moe-
das – to propose a mission in cancer (‘A mission-
oriented approach to cancer in Europe: a joint mis-
sion/vision 2030’) (Celis and Pavalkis, 2017) based on
the activities and objectives of Cancer Core Europe
and Cancer Prevention Europe. The mission states ‘by
combining innovative prevention and treatment strate-
gies in a sustainable state-of-the-art virtual European
cancer centre/infrastructure, it will be possible by 2030
to achieve long-term survival of 3 out of 4 cancer
patients in countries with well-developed healthcare
systems. Furthermore, the concerted actions will pave
the way to handling the economic and social inequali-
ties in countries with less-developed systems’. The can-
cer mission targets the entire cancer research
continuum, engages all the stakeholders and empha-
sises the social impact of cancer research. Moreover, it
differs from the Moonshot programme in the United
States, as it is a bottom-up initiative from the cancer
community that crystallised after many years of con-
tinuous work intended to provide evidence-based
advice to inform policy (Celis and Pavalkis, 2017).
No doubt, creating an effective cancer research con-
tinuum requires substantial resources. Therefore, the
EACS wants, together with other EU cancer organisa-
tions, to persuade the EU and its member states to
formally launch a mission in cancer to boost and
streamline the cancer research continuum in Europe.
3. Vision statement
The EACS is an independent advisory body of well-
recognised medical specialists and researchers, placing
science at the core of policies with the aim of reducing,
at an affordable price, death and suffering caused by
cancer in Europe.
4. Mission
4.1. The EACS strives to create a compelling
interactive continuum of cancer research, from
innovative basic research to implementation of
state-of-the-art evidence-based cancer care and
prevention at an affordable cost
A network of closely collaborating CCCs, each with
outreach to local healthcare organisations, will be
needed to create a system in which access to first-rate
prevention, diagnosis, treatment, cancer care, post-
treatment surveillance and palliation can be guaran-
teed at an affordable cost. To secure quality and foster
effective interactions requires legislation and incentives
from governmental organisations.
The EACS wants to specifically emphasise the issues
that will require further attention to achieve the above.
4.1.1. Support for high-quality basic and preclinical
cancer research
Many of the advances made in recent decades have
been catalysed by basic research, often conducted out-
side the cancer research arena. Oncogenes were first
recognised by virologists, and virus research has con-
tributed significantly to our understanding of what
causes cells to become malignant. Understanding the
principles of genetics, genome organisation and how
mutations are acquired and repaired or not have been
of fundamental importance, as are the insights gained
in cell biology and development, and the many circuits
in cells that control cell behaviour. Much of the pro-
gress was made possible through technological develop-
ments; the sequencing of genomes, RNA and proteins;
the capacity to manipulate genomes of cells; and model
organisms have been invaluable. Single cell analyses
provide further insight into the complexity of tumours
and their microenvironments. The knowledge gathered
on the way has made it possible to mobilise the immune
system of cancer patients to reject their own tumour.
The Next Generation Sequencing technology in con-
junction with high capacity computing (and the promise
of Artificial Intelligence) will permit the integrative
analysis of large datasets. Datasets from cancer patients
have become appealing for formulating and validating
basic research questions relevant for effective preven-
tion, early detection and therapeutic intervention. Over
and over again, nature appears much more complex
than we thought and we continue to be astonished by
the molecular strategies that evolved during evolution
and that are hijacked by cancer cells. Understanding
how nature works should remain an essential
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component of cancer research, as it often permits unex-
pected leaps rather than small steps forward.
The EACS is closely monitoring these developments.
Presently, there is a Memorandum of Understanding
between the EACS and the European Association for
Cancer Research (EACR) to collaborate regarding
strategies to cover the continuum from basic to clinical
research and its subsequent implementation.
4.1.2. Creation of collaborative networks focussed on
primary prevention
Understanding of the aetiology of cancer requires high-
quality epidemiological research with ample access to
registries and patient databases. This could lead to the
identification of risk factors and optimally to their
removal from the environment. In addition, however, it
is equally important to link this to molecular biological
data, to genetics and to available immunological techni-
ques. Research focusing on active prevention measures,
which includes vaccination (primary prevention), sec-
ondary prevention by early diagnosis and removal of
precursor lesions, early removal of existing tumours by
surgery, radiation, chemical or immunological interven-
tions should be promoted. This can substantially reduce
the cancer burden and thereby considerably reduce the
demands on the healthcare system. In particular, this
might contribute to a reduction of the relatively high
burden of cancer in the socioeconomically less-privi-
leged individuals in our society.
4.1.3. Support for research in the area of early detection
Early detection is widely seen as an effective strategy to
reduce the risk of dying from cancer. Whereas screening
has shown value in a subset of cancer types (cervix,
colon, melanoma), in many cases it remains difficult to
detect cancer early enough to eliminate the disease by
local treatment only. Furthermore, even when lesions
can be detected early, it remains questionable what
action is most appropriate. We still lack informative
biomarkers to identify lesions with high risk of pro-
gressing to lethal disease, as it is the case for breast and
prostate. To detect such lesions with sufficient speci-
ficity and sensitivity is still a major bottleneck. The
EACS strongly encourages research within this area.
4.1.4. Support for translational research aimed at
identifying new innovative therapeutic interventions
In spite of the generation of many highly specific drugs
against oncogenic drivers, their therapeutic effects are
in general quite modest. This is almost invariably due
to intrinsic or acquired resistance. Therefore, there is a
need for more sophisticated intervention strategies,
based on detailed insight into the wiring circuits and
heterogeneity of individual tumours. Specific drug
combinations and drug scheduling strategies need to
be explored to overcome this resistance. Predictive can-
cer medicine is considered important, including predic-
tion of both antitumour and side effects. This also
applies to immunotherapy. Finding better predictors
of response, next to more effective mobilisation of the
immune system while limiting the side effects, as well
as strategies to prevent or overcome escapes demand
substantial investments.
This segment of early translational research already
received significant support, but raising funds to test
some of the promising findings in small, well-stratified
patient populations is an increasing bottleneck. It is
essential that phase I/II clinical trials focus on innova-
tive concepts with ample data collection, rather than
iteration of research projects in which the same inter-
vention concept is explored in many parallel trials (e.g.
the many PD1/PDL1 antibody trials). It is important
to note that predictive cancer medicine is important
for guiding both systemic treatment and complement-
ing applications of localised treatments, such as radia-
tion therapy and surgery.
4.1.5. Quality assurance of research environments and
development of strategies to improve the infrastructures
Translational research bridges basic cancer research
with clinical research. It requires an environment of a
CCC in which basic cancer researchers closely interact
with clinical colleagues in a mutually stimulating aca-
demic environment. The effectiveness of such an entity
is determined by the quality of the research, and by
how basic and clinical researchers interact and engage
in joint projects to test new concepts. Such collabora-
tion might originate from basic research or be inspired
by insights obtained from the analysis of clinical data.
The EACS has developed a protocol to assess the
quality of a CCC and certify such centres as a Centre
of Excellence if they meet defined requirements. It per-
mits institutions to further improve their overall qual-
ity as a CCC for the benefit of patients. The EACS
will approach EU and government organisations, as
well as charities, to put incentives in place for Insti-
tutes to join this programme.
The EACS also wants to develop quality assurance
programmes for academic entities that are not part of
a CCC, but significantly contribute to distinct seg-
ments in the cancer research trajectory, for example
cancer biology, genetics, systems biology, drug
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development, local precision treatment, epidemiology,
outcomes research, socio-economics, health-related
quality-of-life research, medical prevention and pallia-
tive care.
4.1.6. Establishment of collaborative networks with
aligned diagnostic and treatment services
Early translational cancer research is of vital impor-
tance. Sufficient capacity to swiftly test new promising
concepts in stratified patient populations within data-
rich innovative clinical trials should have priority. This
is a major challenge. Cancer Core Europe and Cancer
Prevention Europe are exploring how this can be best
implemented in more massive, collaborative structures,
and as such, these organisations can serve as a tem-
plate for the creation of similar parallel structures. To
build expertise, these collaborative networks should
have access to funding mechanisms that facilitate the
creation of infrastructures to effectively conduct such
trials. Substantial funding of these activities (including
the phase I/II trials) through governmental organisa-
tions or health insurers (with umbrella arrangements
with pharma) would help to improve the quality, limit
iterative research, accelerate trial execution and result
in more effective treatments at an affordable cost.
4.1.7. Support for research that can assess the
effectiveness of prevention, early detection and clinical
interventions
We need to evaluate whether new treatment protocols
based on clinical trials retain the claimed benefits of
broader implementation and assess the effectiveness for
patients and the consequences for the healthcare system.
The latter is particularly important for new anticancer
agents that go to market without sufficient information
about clinical effectiveness related to survival and
health-related quality of life, as well as consequences for
the healthcare system. Health economics is a missing
piece and should become a structural component of the
cancer research continuum. Agreement on criteria for
evidence and definition of clinical effectiveness is impor-
tant in the context of personalised/precision cancer med-
icine. Reproduction of research outcomes in the
healthcare systems by real-world data from quality-
assured clinical registries is a central component in the
assessment of the clinical utility of innovation and qual-
ity of care. Health-related quality-of-life research should
have a higher priority, being an essential outcome com-
ponent of therapeutic development and should include
analyses of long-term surviving patients.
The EACS supports the integration of prevention
and therapeutics research as executed by Cancer Core
Europe and Cancer Prevention Europe. Obviously,
early detection is relevant both for secondary preven-
tion and therapeutic intervention, since cancer at an
early phase of development can be more effectively
treated, reducing mortality and morbidity. The EACS
will continue to identify and work towards bridging
any gaps in the cancer research continuum from basic
research to the assessment of outcomes for cancer sur-
vivors. The multiple aspects of outcomes research are
at present not well coordinated and structured, and
the EACS will work for a more consistent outcomes
research endeavour.
4.1.8. Development of open science, open innovation and
open to the world
Europe has achieved some critical goals in the last dec-
ades with the creation of large consortia for cancer
therapeutics and prevention research. The possibility
to rollout a European infrastructure for advanced
translational cancer research has now come within
reach, since accreditation methodologies for CCCs and
a programme for assessment of translational cancer
research and designation of CCCs of Excellence are
now operational. With high-quality collaboration
between quality-assured cancer research centres, there
is a possibility in the long-term to establish a virtual
European Cancer Institute, as requested by the former
Commissioner Philippe Busquin and suggested by the
‘Eurocan+Plus’ project.
4.1.9. Adoption of innovations by healthcare
organisations
Innovations with rigorously proven benefits for
patients must be swiftly included in clinical guidelines
to promote broader implementation. Healthcare
organisations and CCCs need to facilitate this process,
which includes implementation of prevention and early
detection programmes. New applications taking advan-
tage of the increasing sophistication of recognition
software, data integration and new algorithms (with
upcoming Artificial Intelligence) offer exciting new
perspectives. Traditionally, health organisations are
somewhat conservative and not in the best position to
stimulate such developments. Here, the EU could take
initiative to install a small board of experts to catalyse
testing and implementation of promising new concepts.
The EACS should aspire to take the lead in establish-
ing such a board.
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4.1.10. Support for high-quality Big Data collections
and intelligent use of these data
There is little doubt that interrogation of large data sets
can yield unexpected new insights, which will benefit
patients (e.g. more effective prevention and treatment).
In the past, many datasets appeared incomplete or of
insufficient quality to make them relatively worthless:
‘garbage in, garbage out’. Whereas collecting high-qual-
ity molecular data (next generation sequencing of gen-
omes, epigenomes and transcriptomes) is becoming
routine, this is still less the case for the associated clini-
cal data. Establishing extensive quality-controlled
patient records that can be shared between institutions
within Europe is even more of a challenge, also for for-
mally collaborating institutes such as those constituting
Cancer Core Europe. Thus, it is urgent to reach an
agreement about the critical set of data (and their qual-
ity parameters) that needs to be collected, to make them
useful for big data analysis. The algorithms to mine the
data optimally, including Artificial Intelligence strate-
gies, will be needed as well, but are unlikely to constitute
a bottleneck. The EACS will pay specific attention to
these quality aspects when advising and assessing insti-
tutions in their designation programme.
4.1.11. Development of initiatives in the area of digital
health
A specific combination of easily measurable parame-
ters might turn out to be indicative for early disease.
Furthermore, simple measurements might also permit
monitoring of disease progression or relapse early on.
Digital health approaches could play a prominent role
in this. The EACS wants to promote these develop-
ments by inviting experts in digital health to join
forces with renowned cancer pathologist to explore
this specific field and to report on it.
5. European Cancer Science Policy: an
unmet need
To address the issues pinpointed above will require
foresight as well as the extensive and continuous provi-
sion of evidence-based advice to inform policy.
Towards this end, the EACS has strengthened the pol-
icy work by establishing a Scientific Policy Committee
based on multiple competencies. Policy issues under
consideration include: (a) the organization of research
and funding mechanisms needed to develop sustainable
translational cancer medicine; (b) governance and
expansion of existing consortia for therapeutics and
prevention; (c) structuring the interaction between
basic/preclinical research centres, professional clinical
and prevention research organisations, and consortia
of CCCs; (d) updates of accreditation methodologies
for CCCs as well as Designation of CCCs of Excel-
lence; (e) structuring of the health care by expanding
the number of CCCs with formalised responsibility for
outreach areas to bridge research and multidisciplinary
health care and decrease inequalities in the European
countries; (f) development of strategies to achieve cost-
effective cancer care and prevention in the long run;
(g) long-term follow-up for assessment of cancer sur-
vivorship; (h) the engagement of all the key stakehold-
ers, including patient organisations; and (i)
sustainability of actions.
The Committee will prioritise areas of policy action
taking into consideration the urgent need to link
research with the healthcare systems as well as the
opportunities that a cancer mission will bring to
ensure that in the long run, science-driven and social
innovations reach patients across the healthcare
systems in Europe.
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